Japan's Shionogi starts Phase II/III clinical trial for new COVID-19 vaccine

Japan' Shionogi & Co said it had started a Phase II/III clinical trial for its COVID-19 vaccine candidate. The trial for the recombinant protein-based vaccine will take place in Japan and follows a Phase I trial in the country, Shionogi said in a statement. The company will also prepare to conduct multiple trials globally, it said.